Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Authors

Narendranath Epperla, The Ohio State University
Lauren Shea, Washington University School of Medicine in St. Louis
Nancy L Bartlett, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Hematology & Oncology

Publication Date

5-8-2023

Volume

16

Issue

1

First Page

49

Document Type

Open Access Publication

DOI

10.1186/s13045-023-01448-y

Rights and Permissions

Epperla, N., Welkie, R.L., Torka, P. et al. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. J Hematol Oncol 16, 49 (2023). https://doi.org/10.1186/s13045-023-01448-y This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Recommended Citation

Epperla, Narendranath; Shea, Lauren; Bartlett, Nancy L; and et al., "Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study." Journal of Hematology & Oncology. 16, 1. 49 (2023).
https://digitalcommons.wustl.edu/oa_4/2814

Additional Links

Supplemental material is available for this article at publisher site.